Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02964416 |
Recruitment Status :
Completed
First Posted : November 16, 2016
Results First Posted : August 4, 2020
Last Update Posted : August 4, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Neoplasm | Drug: Injection Tramadol Other: placebo | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery |
Actual Study Start Date : | March 2016 |
Actual Primary Completion Date : | March 2018 |
Actual Study Completion Date : | December 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Tramadol
Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
|
Drug: Injection Tramadol
Other Name: Tramal |
Placebo Comparator: Placebo
0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
|
Other: placebo
0.9% Normal saline in 10 ml syringe
Other Name: normal saline |
- Haemodynamic Parameters at the Time of Emergence and Postextubation [ Time Frame: Systolic BP from the time of extubation till 6 hours post operatively ]Systolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation.
- Haemodynamic Parameters at the Time of Emergence and Postextubation [ Time Frame: HR from the time of extubation till 6 hours post operatively ]Heart rate will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If haemodynamic values of heart rate rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation.
- Haemodynamic Parameters at the Time of Emergence and Postextubation [ Time Frame: Diastolic BP from the time of extubation till 6 hours post operatively ]Diastolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation.
- Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Cough on Cough Scale. [ Time Frame: Cough at the time of emergence ]
Cough will be described on following scale 5 = No coughing or straining, 4 = Very smooth minimal coughing, 3 = Moderate coughing, 2 = Marked coughing or straining,
1 = Poor extubation
Cough will be recorded on the above mentioned scale by resident/consultant at following time intervals of emergence
- At resumption of spontaneous breathing,
- Ability to respond to verbal commands
- At cuff deflation
- At extubation
- 2 minutes after extubation. It will be noted if it occurs during emergence at the above mentioned time intervals. Absence of it will be considered as smooth emergence.
- Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Laryngospasm and Bronchospasm. [ Time Frame: at the time of extubation till 6 hours postoperatively ]If there is any episode of bronchospasm or laryngospasm, it will be noted if it occured during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence
- Measure the Quality of Emergence From General Anaesthesia by Measuring Sedation Score [ Time Frame: at the time of extubation till 6 hours postoperatively ]
If there is any episode of sedation it will be noted if it occurs during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence.
sedation score will be used as 0= no sedation, 1= mildly sedated (eye opening on verbal commands), 2= moderately sedated ( awakens on giving pain), 3= deeply sedated ( not waking up even on pain)
- Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring PONV [ Time Frame: at Recovery Room , 2, 4 and 6 hours postoperatively ]Post operative nausea vomiting will be recorded at RR, 2, 4 and 6 hours postoperatively. If there is any episode of PONV it will be noted. Absence of it will be considered as smooth emergence
- Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring Convulsions [ Time Frame: at Recovery Room, 2, 4 and 6 hours postoperatively ]Convulsions will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively.If there is any episode of convulsion, it will be noted. Absence of it will be considered as smooth emergence.
- Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring GCS [ Time Frame: at Recovery Room, 2, 4 and 6 hours postoperatively ]
Post operative Glasgow Coma Scale (GCS) will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively. If there is any deterioration in GCS less than 8/15, Patients will be intubated.
GCS categories <8 Low GCS 9-12 Intermediate GCS 13-15 Full GCS
- Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Mointoring Requirement of Analgesia [ Time Frame: At Recovery room, 2, 4 and 6 hours postoperatively ]Requirement of analgesia will be recorded at recovery room, 2, 4 and 6 hours postoperatively. If there is any need of analgesic, it will be noted and will be considered as one of the determinants of poor quality of emergence.
- Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Episodes of Denaturation [ Time Frame: at the time of extubation ]
If there is any episodes of denaturation (Oxygen saturation <92%), it will be noted it it is occurring during emergence.
Absence of it will be considered as smooth emergence

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with craniotomy for supratentorial tumors under general anesthesia
- American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients
- Elective surgery
- Patients with Glasgow Coma Scale (GCS) 15/15
Exclusion Criteria:
- Patients with a history of allergy or hypersensitivity to tramadol.
- History of epilepsy or convulsions due to any reason.
- Chronic usage of analgesic drugs.
- Patients using monoamine oxidase inhibitors.
- Patients with clinical signs of raised ICP.
- Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2)
- Language barrier.
- Patients taking B-blockers or Ca channel blockers.
- Patients above 65 years of age ( Physiology difference)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02964416
Pakistan | |
Aga Khan University | |
Karachi, Sindh, Pakistan, 74800 |
Principal Investigator: | Asma A Salam, MCPS, FCPS | Aga Khan University |
Documents provided by Asma Abdus Salam, Aga Khan University:
Responsible Party: | Asma Abdus Salam, Senior Instructor, Aga Khan University |
ClinicalTrials.gov Identifier: | NCT02964416 |
Other Study ID Numbers: |
2954-Ane-ERC-14 |
First Posted: | November 16, 2016 Key Record Dates |
Results First Posted: | August 4, 2020 |
Last Update Posted: | August 4, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
supratentorial craniotomy extubation response emergence tramadol |
Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tramadol Analgesics, Opioid Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |